New analysis reveals major gaps in US TNBC trial access, leaving rural and minority communities with fewer treatment options ...
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple ...
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET ...
Rusfertide (Mimrylo) significantly improved hematocrit control and reduced the need for therapeutic phlebotomy in patients ...
Vojnic is director of neuro-oncology at Rutgers Cancer Institute and system leader for neuro-oncology at RWJBarnabas Health.
The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial. The National Comprehensive Cancer Network (NCCN) has ...
Swiecicki, MD, of the University of Michigan Rogel Cancer Center, characterizes the safety and tolerability of subcutaneous ...
Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...
How to Select First-Line Immunotherapy for Metastatic NSCLC: PD-L1, Disease Burden, and Co-Mutations
Matthew Gubens, MD, MS, explains how PD-L1 expression, disease burden, and co-mutations guide first-line immunotherapy selection in metastatic non–small cell lung cancer. Selecting first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results